Patents by Inventor Hongmei Mo

Hongmei Mo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10456414
    Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: October 29, 2019
    Assignee: Gilead Pharmasset LLC
    Inventors: William E. Delaney, IV, John O. Link, Hongmei Mo, David W. Oldach, Adrian S. Ray, William J. Watkins, Cheng Yong Yang
  • Publication number: 20170348342
    Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
    Type: Application
    Filed: January 19, 2017
    Publication date: December 7, 2017
    Inventors: Miriam Michelle Berrey, Melissa Jean Casteel, Darryl G. Cleary, Christy M. Hebner, Robert G. Hindes, Hongmei Mo, Reza Oliyai, Rowchanak Pakdaman, Adrian S. Ray, Charles J. Reynolds, Dimitrios Stefanidis, William T. Symonds, Vahid Zia
  • Publication number: 20170189439
    Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
    Type: Application
    Filed: January 6, 2017
    Publication date: July 6, 2017
    Inventors: William E. Delaney, IV, John O. Link, Hongmei Mo, David W. Oldach, Adrian S. Ray, William J. Watkins, Cheng Yong Yang
  • Publication number: 20170042961
    Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
    Type: Application
    Filed: August 23, 2016
    Publication date: February 16, 2017
    Inventors: William E. Delaney, IV, John O. Link, Hongmei Mo, David W. Oldach, Adrian S. Ray, William J. Watkins, Cheng Yong Yang, Weidong Zhong
  • Patent number: 9549941
    Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: January 24, 2017
    Assignee: Gilead Pharmasset LLC
    Inventors: Darryl G. Cleary, Charles J. Reynolds, Miriam Michelle Berrey, Robert G. Hindes, William T. Symonds, Adrian S. Ray, Hongmei Mo, Christy M. Hebner, Reza Oliyai, Vahid Zia, Dimitrios Stefanidis, Rowchanak Pakdaman, Melissa Jean Casteel
  • Publication number: 20160354425
    Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
    Type: Application
    Filed: June 13, 2016
    Publication date: December 8, 2016
    Inventors: William E. Delaney, IV, John O. Link, Hongmei Mo, David W. Oldach, Adrian S. Ray, William J. Watkins, Cheng Yong Yang
  • Patent number: 9452154
    Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: September 27, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: William E. Delaney, IV, John O. Link, Hongmei Mo, David W. Oldach, Adrian S. Ray, William J. Watkins, Cheng Yong Yang, Weidong Zhong
  • Patent number: 9393256
    Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: July 19, 2016
    Assignee: Gilead Pharmasset LLC
    Inventors: Adrian S. Ray, John O. Link, David W. Oldach, William E. Delaney, IV, Hongmei Mo, Cheng Yong Yang
  • Publication number: 20150150896
    Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
    Type: Application
    Filed: November 11, 2014
    Publication date: June 4, 2015
    Inventors: Darryl G. Cleary, Charles J. Reynolds, Miriam Michelle Berrey, Robert G. Hindes, William T. Symonds, Adrian S. Ray, Hongmei Mo, Christy M. Hebner, Reza Oliyai, Vahid Zia, Dimitrios Stefanidis, Rowchanak Pakdaman, Melissa Jean Casteel
  • Publication number: 20150141353
    Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
    Type: Application
    Filed: October 14, 2014
    Publication date: May 21, 2015
    Inventors: William E. Delaney, IV, John O. Link, Hongmei Mo, David W. Oldach, Adrian S. Ray, William J. Watkins, Cheng Yong Yang, Weidong Zhong
  • Publication number: 20150072418
    Abstract: Replicons of genotype 4d hepatitis C virus (HCV) are provided. These replicons contain adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 4d replicons and methods of using these replicons to screen antiviral agents are also provided.
    Type: Application
    Filed: August 14, 2014
    Publication date: March 12, 2015
    Inventors: HADAS DVORY-SOBOL, CHRISTY HEBNER, HONGMEI MO, SIMIN XU
  • Patent number: 8889159
    Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: November 18, 2014
    Assignee: Gilead Pharmasset LLC
    Inventors: Darryl G. Cleary, Charles J. Reynolds, Miriam Michelle Berrey, Robert G. Hindes, William T. Symonds, Adrian S. Ray, Hongmei Mo, Christy M. Hebner, Reza Oliyai, Vahid Zia, Dimitrios Stefanidis, Rowchanak Pakdaman, Melissa Jean Casteel
  • Patent number: 8889848
    Abstract: Replicons of genotype 3 of hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 3 replicons and methods of using these replicons to screen antiviral agents are also provided.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: November 18, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Mei Yu, Amoreena Corsa
  • Patent number: 8889849
    Abstract: Replicons of genotype 4 hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 4 replicons and methods of using these replicons to screen antiviral agents are also provided.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: November 18, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Betty Peng
  • Publication number: 20130273005
    Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
    Type: Application
    Filed: December 8, 2011
    Publication date: October 17, 2013
    Applicant: GILEAD SCIENCES, INC.
    Inventors: William E. Delaney, John O. Link, Hongmei Mo, David W. Oldach, Adrian S. Ray, William J. Watkins, Cheng Yong Yang, Weidong Zhong
  • Publication number: 20130052633
    Abstract: Replicons of genotype 3 of hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 3 replicons and methods of using these replicons to screen antiviral agents are also provided.
    Type: Application
    Filed: July 5, 2012
    Publication date: February 28, 2013
    Applicant: Gilead Sciences, Inc.
    Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Mei Yu, Amoreena Corsa
  • Publication number: 20130052634
    Abstract: Replicons of genotype 4 hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 4 replicons and methods of using these replicons to screen antiviral agents are also provided.
    Type: Application
    Filed: July 5, 2012
    Publication date: February 28, 2013
    Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Betty Peng
  • Patent number: 8338605
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: December 25, 2012
    Assignee: Abbott Laboratories
    Inventors: Todd W. Rockway, David A. Betebenner, Allan C. Krueger, Nobuhiko Iwasaki, Curt S. Cooper, David D. Anderson, Dale J. Kempf, Darold L. Madigan, Christopher E. Motter, Jason P. Shanley, Michael D. Tufano, Rolf Wagner, Rong Zhang, Akteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V. L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu
  • Patent number: 8236950
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: August 7, 2012
    Assignee: Abbott Laboratories
    Inventors: David A. Betebenner, Clarence J. Maring, Todd W. Rockway, Curt S. Cooper, David D. Anderson, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu
  • Publication number: 20110160233
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Application
    Filed: December 19, 2007
    Publication date: June 30, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: David A. Betebenner, Clarence J. Maring, Todd W. Rockway, Curt S. Cooper, David D. Anderson, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie VL. Masse, Robert J. Carrick, Wenping He, Liangjun Lu